At Cardiff Oncology, our mission is to turn the tide on cancer by developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options to overcome resistance, improve response and increase overall survival.
Onvansertib, our investigational drug, is demonstrating safety and clinical benefit in all three of our ongoing clini...
At Cardiff Oncology, our mission is to turn the tide on cancer by developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options to overcome resistance, improve response and increase overall survival.
Onvansertib, our investigational drug, is demonstrating safety and clinical benefit in all three of our ongoing clinical trials.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.